Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Huvepharma Inc
WARNING LETTER
•Huvepharma Inc•February 28, 2013

Huvepharma Inc – FDA Warning Letter, Feb 28, 2013

Record Details

An FDA inspection of Huvepharma, Inc. in St. Louis, MO, conducted from February 14-28, 2013, revealed significant deviations from Current Good Manufacturing Practice (cGMP) for Type A medicated articles, as per 21 CFR Part 226. These deficiencies cause the firm's products to be adulterated under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act. Key violations included the firm's failure to adhere to established potency specifications for incoming active pharmaceutical ingredients (API), specifically Salinomycin, leading to the use of subpotent material in manufacturing Sacox 60. Additionally, drug component containers were not properly stored to prevent mix-ups and contamination, with rejected API found outside quarantine and a recurring issue with a superpotent recalled lot. Lastly, buildings used for production and storage lacked adequate temperature and humidity controls, resulting in raw materials and finished products being stored outside their labeled ranges, a recurring observation from prior inspections. Huvepharma's March 11, 2013, response to the FDA-483 was acknowledged, with corrective actions to be verified. The FDA requires immediate steps to correct deficiencies and prevent recurrence within 15 working days, including clarifying the root cause of low Salinomycin potency, providing LOD testing results, and potentially revising specifications. Failure to comply may lead to regulatory actions such as seizure or injunction.

Company
Huvepharma Inc
Inspection date
February 28, 2013
Product type
Food
Office
Kansas City District Office
Person
  • John W. Thorsky (District Director)
View Company Profile

ID · 139ad5d4-a365-4138-8272-e0225426a709

Violation Codes5
21 CFR 22621 U.S.C. 351(a)(2)(B)21 CFR 226.58(a)21 CFR 226.40(b)21 CFR 226.20(b)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Huvepharma Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.